This is a test that measures how well your blood clots. It looks at the shape and strength of the clot you form. It helps doctors understand how your blood clotting system is working.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Thrombelastography, usually called TEG, is a blood test that watches a small sample of blood form a clot and then break it down, recording the whole process as a curve. It shows how long a clot takes to start, how quickly it builds, how strong it becomes and whether it dissolves too early. A closely related test, thromboelastometry (often known by the device name ROTEM), works on the same principle. Doctors group them together as viscoelastic tests. Standard clotting tests, such as the INR (international normalized ratio, a measure of how long plasma takes to clot) and a platelet count, each look at one part of clotting. They do not show how well platelets actually work or whether a clot is breaking down too fast, and their results can take longer to come back. TEG fills those gaps and is often run close to the bedside or operating room. Its main job is to guide treatment when someone is bleeding heavily or is likely to. During heart surgery, liver transplantation or after major trauma, clotting can fail in several ways at once, and TEG helps the team decide which blood products a person actually needs, such as plasma, platelets or fibrinogen (the protein that forms the clot's mesh), rather than giving them all. It is also used in intensive care and in people with advanced liver disease. A variant called platelet mapping estimates how strongly antiplatelet medicines are affecting platelets, which can help with timing surgery for someone who takes them. TEG is not a general screening test. Before routine surgery, a careful history of past bleeding and a physical examination remain the main way to tell who is at higher risk of bleeding.
For most people there is little to prepare. TEG is often ordered in the middle of surgery, in intensive care or in an emergency, so a person may not know it was done until later. When it is planned, the lab's instructions focus on how the sample is collected and handled rather than on fasting, but follow any instructions your care team gives. It matters that the team knows about every medicine that affects clotting, including heparin, warfarin, newer blood thinners and antiplatelet medicines such as clopidogrel. These medicines change the result. Heparin, which is common in hospitals, can be neutralized in a second version of the test so the team can see how the blood would clot without it. Do not stop a blood thinner on your own for this test; any change is a decision for the prescribing team.
A small amount of blood is drawn into a tube containing citrate, a chemical that stops the blood from clotting until the test begins. The sample has to reach the analyzer quickly, often within minutes and generally within two hours, because blood that sits too long gives unreliable results. In the analyzer, the blood sits in a small cup with a pin. As a clot forms, it links the cup and pin, and the machine records that movement as a curve that widens as the clot strengthens and narrows if it breaks down. Different versions of the test add chemicals that start clotting in particular ways, block platelets to isolate fibrinogen, or neutralize heparin, so the team can pinpoint which part of clotting is not working. The part a patient feels is only the blood draw: a brief sting from the needle, unless the sample comes during surgery or under sedation.
There is no recovery from the test itself beyond the blood draw. Some throbbing or a small bruise where the needle went in is common and fades on its own. The report has a few main numbers, and each points toward a different fix. The R time (reaction time) is how long the first strands of clot take to appear; a long R time suggests clotting factors are low, which is often treated with plasma. The angle shows how fast the clot builds. The MA (maximum amplitude) is the clot's peak strength, which depends mostly on platelets and fibrinogen; a weak clot may call for platelets or fibrinogen. LY30 is the percentage of the clot that has broken down 30 minutes after it reaches peak strength; a high value suggests clot breakdown is excessive, which is treated differently from a shortage of clotting factors. A normal result can be just as useful, because it can spare someone a transfusion they do not need. Normal ranges depend on the lab and the device. TEG and ROTEM report similar measures under different names, and their numbers are not interchangeable, so results are compared only with the reporting lab's own ranges and with earlier tests on the same system.
The test itself carries only the small risks of any blood draw. Its importance lies in the decisions it shapes: blood transfusions can cause reactions ranging from fever to serious lung injury, so giving only the products a person needs has real value. The evidence about benefit is still limited. A 2026 Cochrane review of 35 randomized trials found that using TEG or ROTEM to guide transfusion may reduce bleeding, the use of plasma and platelets, the need to return to the operating room and possibly deaths, but the certainty of that evidence is very low. Most trials involved adults having planned heart surgery, so the findings may not apply equally to trauma, childbirth, children or critical illness. The test also has technical limits. It measures clotting in a still cup, which does not fully mimic fast-flowing blood in arteries. Heparin, sample delays and differences between devices can all distort results, which is why the team reads TEG alongside standard tests and how a person is actually bleeding.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Thrombelastography, what to expect, or ask the community a question.